Table 1.

The correlation between the p53 codon 72 polymorphic variants and pretreatment patient characteristics or treatment regimens

Total (n)Pro/Pro, n (%)Pro/Arg, n (%)Arg/Arg, n (%)P
Chemotherapy regimens
    FEC145 (21.7)5 (9.1)4 (12.5)0.277
    CAF72 (8.7)3 (5.5)2 (6.3)
    CTF8916 (69.6)47 (85.4)26 (81.2)
Menopausal status0.959
    Premenopausal7716 (69.6)38 (69.1)23 (71.9)
    Postmenopausal337 (30.4)17 (30.9)9 (28.1)
ER status0.904
    Positive7215 (68.2)39 (76.5)18 (58.1)
    Negative327 (31.8)12 (23.5)13 (41.9)
    ND6141
PR status0.411
    Positive6011 (50.0)33 (64.7)16 (51.6)
    Negative4411 (50.0)18 (35.3)15 (48.4)
    ND6141
erbB2 status0.114
    Positive4613 (59.1)17 (32.7)16 (53.3)
    Negative589 (40.9)35 (67.3)14 (46.7)
    ND6132
Clinical stage0.828
    I245 (21.7)13 (23.6)6 (18.8)
    I6513 (56.6)32 (58.2)20 (62.4)
    III215 (21.7)10 (18.2)6 (18.8)
Tumor size (cm)0.756
    <37014 (60.9)35 (63.6)21 (65.6)
    ≥3409 (39.1)20 (36.4)11 (34.4)
  • Abbreviations: ER, estrogen receptor; PR, progesterone receptor; ND, nondetection.